LT3359185T - Priešnavikinė kompozicija - Google Patents
Priešnavikinė kompozicijaInfo
- Publication number
- LT3359185T LT3359185T LTEPPCT/FR2016/052598T LT16052598T LT3359185T LT 3359185 T LT3359185 T LT 3359185T LT 16052598 T LT16052598 T LT 16052598T LT 3359185 T LT3359185 T LT 3359185T
- Authority
- LT
- Lithuania
- Prior art keywords
- tumoral
- composition
- tumoral composition
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1559589A FR3042121A1 (fr) | 2015-10-08 | 2015-10-08 | Composition anti-tumorale |
FR1659450A FR3042122B1 (fr) | 2015-10-08 | 2016-09-30 | Composition anti-tumorale |
PCT/FR2016/052598 WO2017060650A1 (fr) | 2015-10-08 | 2016-10-07 | Composition anti-tumorale |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3359185T true LT3359185T (lt) | 2022-06-27 |
Family
ID=55178130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/FR2016/052598T LT3359185T (lt) | 2015-10-08 | 2016-10-07 | Priešnavikinė kompozicija |
Country Status (14)
Country | Link |
---|---|
US (2) | US20180296653A1 (lt) |
EP (1) | EP3359185B1 (lt) |
JP (1) | JP7211815B2 (lt) |
KR (1) | KR20180059547A (lt) |
CN (1) | CN108348587A (lt) |
CA (1) | CA2999948C (lt) |
DK (1) | DK3359185T3 (lt) |
ES (1) | ES2919134T3 (lt) |
FR (2) | FR3042121A1 (lt) |
HK (1) | HK1253315A1 (lt) |
IL (1) | IL258430B (lt) |
LT (1) | LT3359185T (lt) |
RU (1) | RU2728748C2 (lt) |
WO (1) | WO2017060650A1 (lt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
CN116676324B (zh) * | 2023-07-28 | 2023-10-27 | 四川大学华西医院 | 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751879B1 (fr) * | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
EP0951555A2 (en) | 1996-09-24 | 1999-10-27 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
WO1999015692A2 (en) | 1997-09-23 | 1999-04-01 | Bavarian Nordic Research Institute A/S | Dengue virus antigens and treatment of dengue fever |
EE05633B1 (et) | 2000-03-14 | 2013-02-15 | Mayr Anton | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine |
AU2002231639B2 (en) | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
UA82466C2 (uk) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
CA2466413C (en) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
UA78738C2 (en) | 2001-12-10 | 2007-04-25 | Bavarian Nordic As | Composition containing cowpox virus and method for its preparation |
EA006485B1 (ru) | 2001-12-20 | 2005-12-29 | Бавариан Нордик А/С | Способ выделения и очистки поксвирусов из инфицированных клеток |
EA011233B1 (ru) | 2002-04-19 | 2009-02-27 | Бавариан Нордик А/С | Применение модифицированного вируса осповакцины анкара для вакцинации новорожденных |
SI1407033T1 (sl) | 2002-05-16 | 2006-06-30 | Bavarian Nordic As | Intergenske regije kot insercijska mesta v genomumodificiranega virusavakcinije Ankara (MVA) |
ES2256747T3 (es) | 2002-05-16 | 2006-07-16 | Bavarian Nordic A/S | Expresion de genes en el virus de la vacuna modificado, usando el promotor ati de la viruela de la vaca. |
DK1506223T3 (da) | 2002-05-16 | 2006-04-10 | Bavarian Nordic As | Fusionsprotein af regulatoriske/accessoriske HIV-proteiner |
GB0221574D0 (en) * | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
US7785778B2 (en) | 2002-11-25 | 2010-08-31 | University Of Copenhagen | Porcine polymorphisms and methods for detecting them |
AU2003293675B2 (en) | 2002-11-25 | 2009-04-23 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ATI promoters |
WO2004092212A2 (en) * | 2003-04-15 | 2004-10-28 | Sanofi Pasteur Limited | Tumor antigens bfa5 for prevention and/or treatment of cancer |
DK1845164T3 (da) | 2003-11-24 | 2010-09-20 | Bavarian Nordic As | Promoterer til ekspression i modificeret vacciniavirus ankara |
MX2007010158A (es) | 2005-02-23 | 2007-10-16 | Bavarian Nordic As | Uso de un poxvirus modificado para la induccion rapida de inmunidad contra un poxvirus u otros agentes infecciosos. |
EP2064351A1 (en) | 2006-09-08 | 2009-06-03 | Bavarian Nordic A/S | Phenotypic and genotypic differences of mva strains |
EP2596801B1 (en) | 2006-10-06 | 2018-05-02 | Bavarian Nordic A/S | Recombinant modified vaccinia ankara virus encoding a her-2 antigen for use in treating cancer |
US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
JP5721428B2 (ja) | 2007-04-27 | 2015-05-20 | バヴァリアン・ノルディック・アクティーゼルスカブ | マクロファージ−コロニー刺激因子(m−csf)による樹状細胞発生の誘導 |
WO2008138533A1 (en) | 2007-05-14 | 2008-11-20 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
NZ601827A (en) | 2007-10-18 | 2014-01-31 | Bavarian Nordic Inc | Use of mva to treat prostate cancer |
AU2009253730A1 (en) | 2008-05-26 | 2009-12-03 | Tyrian Diagnostics Limited | Method of diagnosis of infection by mycobacteria and reagents therefor |
EP2303322A1 (en) | 2008-06-20 | 2011-04-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
NZ602322A (en) | 2008-11-21 | 2013-12-20 | Bavarian Nordic As | Vector comprising multiple homologous nucleotide sequences |
EP2367944B1 (en) | 2008-11-27 | 2019-01-09 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
GB0901593D0 (en) | 2009-01-30 | 2009-03-11 | Touchlight Genetics Ltd | Production of closed linear DNA |
US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
KR20120093941A (ko) | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 hiv에 대한 광범위한 t-세포 반응의 생성 |
JP5783642B2 (ja) | 2010-01-28 | 2015-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | Mvaの主なゲノム欠失を含むワクシニアウイルス変異体 |
NZ603620A (en) | 2010-07-20 | 2015-01-30 | Bavarian Nordic As | Method for harvesting expression products |
GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
CA2813685A1 (en) | 2010-10-15 | 2012-04-19 | Josef Weigl | Recombinant modified vaccinia virus ankara influenza vaccine |
CA2815727C (en) | 2010-11-05 | 2019-09-10 | Bavarian Nordic A/S | Modulation of immune responses by the poxviral k4 protein |
WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
EP2864487B1 (en) | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
CN109266622B (zh) | 2012-08-01 | 2023-05-09 | 巴法里安诺迪克有限公司 | 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗 |
EP3639851A1 (en) | 2012-09-04 | 2020-04-22 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
JP2016502507A (ja) | 2012-10-19 | 2016-01-28 | バヴァリアン・ノルディック・インコーポレイテッド | 癌治療のための組成物および方法 |
IN2015DN03326A (lt) | 2012-10-28 | 2015-10-09 | Bavarian Nordic As | |
US9402888B2 (en) * | 2013-03-14 | 2016-08-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
KR20160070095A (ko) * | 2013-11-05 | 2016-06-17 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제 |
AU2014368898B2 (en) * | 2013-12-20 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Combination therapy with neoantigen vaccine |
EP3283088A4 (en) * | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
-
2015
- 2015-10-08 FR FR1559589A patent/FR3042121A1/fr active Pending
-
2016
- 2016-09-30 FR FR1659450A patent/FR3042122B1/fr active Active
- 2016-10-07 CA CA2999948A patent/CA2999948C/fr active Active
- 2016-10-07 WO PCT/FR2016/052598 patent/WO2017060650A1/fr active Application Filing
- 2016-10-07 US US15/766,510 patent/US20180296653A1/en not_active Abandoned
- 2016-10-07 JP JP2018515877A patent/JP7211815B2/ja active Active
- 2016-10-07 KR KR1020187012825A patent/KR20180059547A/ko not_active Application Discontinuation
- 2016-10-07 DK DK16794685.4T patent/DK3359185T3/da active
- 2016-10-07 LT LTEPPCT/FR2016/052598T patent/LT3359185T/lt unknown
- 2016-10-07 CN CN201680058083.7A patent/CN108348587A/zh active Pending
- 2016-10-07 EP EP16794685.4A patent/EP3359185B1/fr active Active
- 2016-10-07 RU RU2018115534A patent/RU2728748C2/ru active
- 2016-10-07 ES ES16794685T patent/ES2919134T3/es active Active
-
2018
- 2018-03-28 IL IL258430A patent/IL258430B/en unknown
- 2018-10-02 HK HK18112608.9A patent/HK1253315A1/zh unknown
-
2021
- 2021-01-19 US US17/152,031 patent/US20210138053A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FR3042122B1 (fr) | 2020-01-17 |
RU2018115534A3 (lt) | 2020-02-26 |
KR20180059547A (ko) | 2018-06-04 |
HK1253315A1 (zh) | 2019-06-14 |
US20180296653A1 (en) | 2018-10-18 |
EP3359185A1 (fr) | 2018-08-15 |
US20210138053A1 (en) | 2021-05-13 |
ES2919134T3 (es) | 2022-07-22 |
FR3042122A1 (fr) | 2017-04-14 |
JP7211815B2 (ja) | 2023-01-24 |
WO2017060650A1 (fr) | 2017-04-13 |
IL258430B (en) | 2022-03-01 |
EP3359185B1 (fr) | 2022-04-06 |
CN108348587A (zh) | 2018-07-31 |
CA2999948C (fr) | 2024-04-23 |
CA2999948A1 (fr) | 2017-04-13 |
RU2018115534A (ru) | 2019-11-08 |
RU2728748C2 (ru) | 2020-07-31 |
IL258430A (en) | 2018-06-28 |
DK3359185T3 (da) | 2022-07-04 |
FR3042121A1 (fr) | 2017-04-14 |
JP2018531238A (ja) | 2018-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201512030D0 (en) | Composition | |
GB201521507D0 (en) | Composition | |
GB201505527D0 (en) | Composition | |
GB201506827D0 (en) | Composition | |
GB201515640D0 (en) | Composition | |
GB201506825D0 (en) | Composition | |
GB201506829D0 (en) | Composition | |
GB201506830D0 (en) | Composition | |
GB2545773B (en) | Composition | |
GB201522603D0 (en) | Composition | |
GB201506828D0 (en) | Composition | |
HK1253315A1 (zh) | 抗腫瘤組合物 | |
GB201518348D0 (en) | Composition | |
GB201514585D0 (en) | Composition | |
GB201511697D0 (en) | Composition | |
GB201509044D0 (en) | Composition | |
GB201505520D0 (en) | Composition | |
GB201504665D0 (en) | Composition | |
GB201504307D0 (en) | Composition | |
GB201522681D0 (en) | Composition | |
GB201519327D0 (en) | Composition | |
GB2537648B (en) | Composition | |
GB201515639D0 (en) | Composition | |
GB201508722D0 (en) | Composition | |
GB201521384D0 (en) | Composition |